Login Register Cart 0
Generic placeholder image

Current Diabetes Reviews

Editor-in-Chief

ISSN (Print): 1573-3998
ISSN (Online): 1875-6417

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Prevalence and Predictors of Diabetic Peripheral Neuropathy in Newly Diagnosed Type 2 Diabetes Mellitus Patients

In Press, (this is not the final "Version of Record"). Available online 12 February, 2024
Author(s): Pooja Jadhao, Jayshree Swain*, Srijit Das, Swayamsidha Mangaraj and Surapaneni Lakshmi Sravya
Published on: 12 February, 2024

Article ID: e120224226871

DOI: 10.2174/0115733998282818240125110248

Price: $95

Abstract

Aim: The present study aimed to determine the prevalence and predictors of DPN in newly diagnosed T2DM patients.

Background: Diabetic Peripheral Neuropathy (DPN) is the most common and debilitating complication of Type 2 Diabetes Mellitus (T2DM).

Methods: Newly diagnosed T2DM patients visiting the outpatient department were recruited. Detailed demographic parameters, histories, physical examinations, and biochemical investigations were carried out. Patients were screened for DPN using the Diabetic Neuropathy Symptom (DNS) score, the revised Disability Neuropathy Score (NDS), Vibration Perception Threshold (VPT) using a biosthesiometer, and the 10g SW Monofilament Test (MFT).

Results: A total of 350 newly diagnosed T2DM patients (mean age 46.4±13.6 years) were included. The prevalence of DPN was found to be 34% using the combined DNS and NDS scores. VPT was moderately impaired in 18.3% and severely impaired in 12% patients, while MFT revealed a loss of protective sensation in 35.4% patients. After logistic regression analysis, DPN was significantly associated with increasing age (OR 1.08, 95%CI 1.06-1.11), increasing HbA1C levels (OR 1.23, 95%CI 1.05-1.42), increasing TSH levels (OR 1.23, 95%CI 1.05-1.44), presence of hypertension (OR 2.78, 95%CI 1.51-5.11), and reduced BMI (OR 0.9, 95%CI 0.84- 0.99). The sensitivity and specificity of detecting DPN by combining VPT and MFT were 91.6% and 84.2%, respectively.

Conclusion: The prevalence of DPN was high even in newly diagnosed T2DM and associated significantly with increasing age, HbA1C levels, TSH levels, hypertension, and reduced BMI. Earlier screening for DPN, along with aggressive control of glycemia, blood pressure, and hypothyroidism, may be beneficial.

[1]
International Diabetes Federation. IDF Diabetes Atlas 2021. Available from: https://www.diabetesatlas.org
[2]
Pradeepa R, Mohan V. Prevalence of type 2 diabetes and its complications in India and economic costs to the nation. Eur J Clin Nutr 2017; 71(7): 816-24.
[http://dx.doi.org/10.1038/ejcn.2017.40] [PMID: 28422124]
[3]
Mathur P, Leburu S, Kulothungan V. Prevalence, awareness, treatment and control of diabetes in India from the countrywide national ncd monitoring survey. Front Public Health 2022; 10: 748157.
[http://dx.doi.org/10.3389/fpubh.2022.748157] [PMID: 35359772]
[4]
Pop-Busui R, Boulton AJM, Feldman EL, et al. Diabetic neuropathy: A position statement by the American Diabetes Association. Diabetes Care 2017; 40(1): 136-54.
[http://dx.doi.org/10.2337/dc16-2042] [PMID: 27999003]
[5]
Tesfaye S, Boulton AJM, Dyck PJ, et al. Diabetic neuropathies: Update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 2010; 33(10): 2285-93.
[http://dx.doi.org/10.2337/dc10-1303] [PMID: 20876709]
[6]
Ang L, Jaiswal M, Martin C, Pop-Busui R. Glucose control and diabetic neuropathy: Lessons from recent large clinical trials. Curr Diab Rep 2014; 14(9): 528.
[http://dx.doi.org/10.1007/s11892-014-0528-7] [PMID: 25139473]
[7]
Martin CL, Albers JW, Pop-Busui R. Neuropathy and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care 2014; 37(1): 31-8.
[http://dx.doi.org/10.2337/dc13-2114] [PMID: 24356595]
[8]
Volmer-Thole M, Lobmann R. Neuropathy and diabetic foot syndrome. Int J Mol Sci 2016; 17(6): 917.
[http://dx.doi.org/10.3390/ijms17060917] [PMID: 27294922]
[9]
Hicks CW, Selvin E. Epidemiology of peripheral neuropathy and lower extremity disease in diabetes. Curr Diab Rep 2019; 19(10): 86.
[http://dx.doi.org/10.1007/s11892-019-1212-8] [PMID: 31456118]
[10]
Tesfaye S. Recent advances in the management of diabetic distal symmetrical polyneuropathy. J Diabetes Investig 2011; 2(1): 33-42.
[http://dx.doi.org/10.1111/j.2040-1124.2010.00083.x] [PMID: 24843458]
[11]
Boulton AJM, Armstrong DG, Albert SF, et al. Comprehensive foot examination and risk assessment: A report of the task force of the foot care interest group of the American Diabetes Association, with endorsement by the American Association of Clinical Endocrinologists. Diabetes Care 2008; 31(8): 1679-85.
[http://dx.doi.org/10.2337/dc08-9021] [PMID: 18663232]
[12]
Kanji JN, Anglin RE, Hunt DL, Panju A. Does this patient with diabetes have large-fiber peripheral neuropathy? JAMA 2010; 303(15): 1526-32.
[http://dx.doi.org/10.1001/jama.2010.428] [PMID: 20407062]
[13]
Ramsey SD, Newton K, Blough D, et al. Incidence, outcomes, and cost of foot ulcers in patients with diabetes. Diabetes Care 1999; 22(3): 382-7.
[http://dx.doi.org/10.2337/diacare.22.3.382] [PMID: 10097914]
[14]
Carmichael J, Fadavi H, Ishibashi F, Shore AC, Tavakoli M. Advances in screening, early diagnosis and accurate staging of diabetic neuropathy. Front Endocrinol 2021; 12: 671257.
[http://dx.doi.org/10.3389/fendo.2021.671257] [PMID: 34122344]
[15]
Agrawal RP, Ola V, Bishnoi P, Gothwal S, Sirohi P, Agrawal R. Prevalence of micro and macrovascular complications and their risk factors in type-2 diabetes mellitus. J Assoc Physicians India 2014; 62(6): 504-8.
[PMID: 25856915]
[16]
George H, Rakesh P, Krishna M, et al. Foot care knowledge and practices and the prevalence of peripheral neuropathy among people with diabetes attending a secondary care rural hospital in southern India. J Family Med Prim Care 2013; 2(1): 27-32.
[http://dx.doi.org/10.4103/2249-4863.109938] [PMID: 24479039]
[17]
Iunes DH, Rocha CBJ, Borges NCS, Marcon CO, Pereira VM, Carvalho LC. Self-care associated with home exercises in patients with type 2 diabetes mellitus. PLoS One 2014; 9(12): e114151.
[http://dx.doi.org/10.1371/journal.pone.0114151] [PMID: 25479542]
[18]
Bansal D, Gudala K, Muthyala H, Esam HP, Nayakallu R, Bhansali A. Prevalence and risk factors of development of peripheral diabetic neuropathy in type 2 diabetes mellitus in a tertiary care setting. J Diabetes Investig 2014; 5(6): 714-21.
[http://dx.doi.org/10.1111/jdi.12223] [PMID: 25422773]
[19]
Dutta A, Naorem S, Singh T, Wangjam K. Prevalence of peripheral neuropathy in newly diagnosed type 2 diabetics. Int J Diabetes Dev Ctries 2005; 25(1): 30.
[http://dx.doi.org/10.4103/0973-3930.26756]
[20]
Gill HK, Yadav SB, Ramesh V, Bhatia E. A prospective study of prevalence and association of peripheral neuropathy in Indian patients with newly diagnosed type 2 diabetes mellitus. J Postgrad Med 2014; 60(3): 270-5.
[http://dx.doi.org/10.4103/0022-3859.138750] [PMID: 25121366]
[21]
American Diabetes Association. Classification and diagnosis of diabetes: Standards of medical care in diabetes-2021. Diabetes Care 2021; 44 (Suppl. 1): S15-33.
[http://dx.doi.org/10.2337/dc21-S002] [PMID: 33298413]
[22]
Krause SJ, Backonja MM. Development of a neuropathic pain questionnaire. Clin J Pain 2003; 19(5): 306-14.
[http://dx.doi.org/10.1097/00002508-200309000-00004] [PMID: 12966256]
[23]
Meijer JWG, Smit AJ, Sonderen EV, Groothoff JW, Eisma WH, Links TP. Symptom scoring systems to diagnose distal polyneuropathy in diabetes: The Diabetic Neuropathy Symptom score. Diabet Med 2002; 19(11): 962-5.
[http://dx.doi.org/10.1046/j.1464-5491.2002.00819.x] [PMID: 12421436]
[24]
Petropoulos IN, Ponirakis G, Khan A, Almuhannadi H, Gad H, Malik RA. Diagnosing diabetic neuropathy: Something old, something new. Diabetes Metab J 2018; 42(4): 255-69.
[http://dx.doi.org/10.4093/dmj.2018.0056] [PMID: 30136449]
[25]
Dyck PJ. Detection, characterization, and staging of polyneuropathy: Assessed in diabetics. Muscle Nerve 1988; 11(1): 21-32.
[http://dx.doi.org/10.1002/mus.880110106] [PMID: 3277049]
[26]
Abbott CA, Carrington AL, Ashe H, et al. The north-west diabetes foot care study: Incidence of, and risk factors for, new diabetic foot ulceration in a community-based patient cohort. Diabet Med 2002; 19(5): 377-84.
[http://dx.doi.org/10.1046/j.1464-5491.2002.00698.x] [PMID: 12027925]
[27]
Weintrob N, Amitay I, Lilos P, Shalitin S, Lazar L, Josefsberg Z. Bedside neuropathy disability score compared to quantitative sensory testing for measurement of diabetic neuropathy in children, adolescents, and young adults with type 1 diabetes. J Diabetes Complications 2007; 21(1): 13-9.
[http://dx.doi.org/10.1016/j.jdiacomp.2005.11.002] [PMID: 17189869]
[28]
Young MJ, Boulton AJM, MacLeod AF, Williams DRR, Sonksen PH. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia 1993; 36(2): 150-4.
[http://dx.doi.org/10.1007/BF00400697] [PMID: 8458529]
[29]
Chawla A, Bhasin GK, Chawla R. Validation of neuropathy symptoms score (NSS) and neuropathy disability score (NDS). In: The Clinical Diagnosis of Peripheral Neuropathy In Middle Aged People With Diabetes. The Internet Journal of Family Practice. 2013; p. 12.
[30]
Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers in patients with diabetes. JAMA 2005; 293(2): 217-28.
[http://dx.doi.org/10.1001/jama.293.2.217] [PMID: 15644549]
[31]
Shehab DK, Al-Jarallah KF, Abraham M, Mojiminiyi OA, Al-Mohamedy H, Abdella NA. Back to basics: Ankle reflex in the evaluation of peripheral neuropathy in type 2 diabetes mellitus. QJM 2012; 105(4): 315-20.
[http://dx.doi.org/10.1093/qjmed/hcr212] [PMID: 22071964]
[32]
Saha D, Saha K, Dasgupta PK. Vibration sense impairment in diabetes mellitus. Indian J Physiol Pharmacol 2011; 55(4): 381-3.
[PMID: 23362733]
[33]
Ghosal S, Stephens J, Mukherjee A. Quantitative vibration perception threshold in assessing diabetic neuropathy: Is the cut-off value lower for Indian subjects? [Q-VADIS Study]. Diabetes Metab Syndr 2012; 6(2): 85-9. [Q-VADIS Study].
[http://dx.doi.org/10.1016/j.dsx.2012.08.002] [PMID: 23153975]
[34]
Young MJ, Breddy JL, Veves A, Boulton AJM. The prediction of diabetic neuropathic foot ulceration using vibration perception thresholds. A prospective study. Diabetes Care 1994; 17(6): 557-60.
[http://dx.doi.org/10.2337/diacare.17.6.557] [PMID: 8082524]
[35]
McIllhatton A, Lanting S, Lambkin D, Leigh L, Casey S, Chuter V. Reliability of recommended non-invasive chairside screening tests for diabetes-related peripheral neuropathy: a systematic review with meta-analyses. BMJ Open Diabetes Res Care 2021; 9(2): e002528.
[http://dx.doi.org/10.1136/bmjdrc-2021-002528] [PMID: 34952841]
[36]
Booth J, Young MJ. Differences in the performance of commercially available 10 g monofilaments. Diabetes Care 2000; 23(7): 984-8.
[http://dx.doi.org/10.2337/diacare.23.7.984] [PMID: 10895851]
[37]
Zhang Q, Yi N, Liu S, et al. Easier operation and similar power of 10 g monofilament test for screening diabetic peripheral neuropathy. J Int Med Res 2018; 46(8): 3278-84.
[http://dx.doi.org/10.1177/0300060518775244] [PMID: 29808737]
[38]
Schaper NC, Van Netten JJ, Apelqvist J, Lipsky BA, Bakker K. Prevention and management of foot problems in diabetes: A summary guidance for daily practice 2015, based on the IWGDF Guidance Documents. Diabetes Metab Res Rev 2016; 32(S1) (Suppl. 1): 7-15.
[http://dx.doi.org/10.1002/dmrr.2695] [PMID: 26335366]
[39]
Pham H, Armstrong DG, Harvey C, Harkless LB, Giurini JM, Veves A. Screening techniques to identify people at high risk for diabetic foot ulceration: A prospective multicenter trial. Diabetes Care 2000; 23(5): 606-11.
[http://dx.doi.org/10.2337/diacare.23.5.606] [PMID: 10834417]
[40]
Lehtinen JM, Uusitupa M, Siitonen O, Pyörälä K. Prevalence of neuropathy in newly diagnosed NIDDM and nondiabetic control subjects. Diabetes 1989; 38(10): 1307-13.
[http://dx.doi.org/10.2337/diab.38.10.1307] [PMID: 2551761]
[41]
Dyck PJ, Overland CJ, Low PA, et al. Signs and symptoms versus nerve conduction studies to diagnose diabetic sensorimotor polyneuropathy: Cl vs. NPhys trial. Muscle Nerve 2010; 42(2): 157-64.
[http://dx.doi.org/10.1002/mus.21661] [PMID: 20658599]
[42]
Partanen J, Niskanen L, Lehtinen J, Mervaala E, Siitonen O, Uusitupa M. Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995; 333(2): 89-94.
[http://dx.doi.org/10.1056/NEJM199507133330203] [PMID: 7777034]
[43]
Chander K. Prevalence of peripheral neuropathy in newly diagnosed type 2 diabetics in sub-district hospital Bishnah. International Journal of Advances in Med 2021; 8(6): 747.
[http://dx.doi.org/10.18203/2349-3933.ijam20211916]
[44]
Kebede SA, Tusa BS, Weldesenbet AB, Tessema ZT, Ayele TA. Time to diabetic neuropathy and its predictors among newly diagnosed type 2 diabetes mellitus patients in Northwest Ethiopia. Egypt J Neurol Psychiat Neurosurg 2021; 57(1): 147.
[http://dx.doi.org/10.1186/s41983-021-00402-4]
[45]
Sosale A, Prasanna Kumar KM, Sadikot SM, et al. Chronic complications in newly diagnosed patients with type 2 diabetes mellitus in India. Indian J Endocrinol Metab 2014; 18(3): 355-60.
[http://dx.doi.org/10.4103/2230-8210.131184] [PMID: 24944931]
[46]
Uddin F, Ali B, Junaid N. Prevalence of diabetic complications in newly diagnosed type 2 diabetes patients in pakistan: Findings from national registry. J Ayub Med Coll Abbottabad 2018; 30(1): 652-8.
[47]
Abbott CA, Chaturvedi N, Malik RA, et al. Explanations for the lower rates of diabetic neuropathy in Indian asians versus europeans. Diabetes Care 2010; 33(6): 1325-30.
[http://dx.doi.org/10.2337/dc09-2067] [PMID: 20215455]
[48]
Cheng Y, Cao W, Zhang J, et al. Determinants of diabetic peripheral neuropathy and their clinical significance: A retrospective cohort study. Front Endocrinol 2022; 13: 934020.
[http://dx.doi.org/10.3389/fendo.2022.934020] [PMID: 35957831]
[49]
Kostev K, Jockwig A, Hallwachs A, Rathmann W. Prevalence and risk factors of neuropathy in newly diagnosed type 2 diabetes in primary care practices: A retrospective database analysis in Germany and U.K. Prim Care Diabetes 2014; 8(3): 250-5.
[http://dx.doi.org/10.1016/j.pcd.2014.01.011] [PMID: 24530101]
[50]
Win MMTM, Fukai K, Nyunt HH, Hyodo Y, Linn KZ. Prevalence of peripheral neuropathy and its impact on activities of daily living in people with type 2 diabetes mellitus. Nurs Health Sci 2019; 21(4): 445-53.
[http://dx.doi.org/10.1111/nhs.12618] [PMID: 31215149]
[51]
Braffett BH, Gubitosi-Klug RA, Albers JW, et al. Risk factors for diabetic peripheral neuropathy and cardiovascular autonomic neuropathy in the diabetes control and complications trial/epidemiology of diabetes interventions and complications (DCCT/EDIC) study. Diabetes 2020; 69(5): 1000-10.
[http://dx.doi.org/10.2337/db19-1046] [PMID: 32051148]
[52]
Kisozi T, Mutebi E, Kisekka M, et al. Prevalence, severity and factors associated with peripheral neuropathy among newly diagnosed diabetic patients attending Mulago hospital: A cross-sectional study. Afr Health Sci 2017; 17(2): 463-73.
[http://dx.doi.org/10.4314/ahs.v17i2.21] [PMID: 29062342]
[53]
Sendi RA, Mahrus AM, Saeed RM, Mohammed MA, Al-Dubai SAR. Diabetic peripheral neuropathy among Saudi diabetic patients: A multicenter cross-sectional study at primary health care setting. J Family Med Prim Care 2020; 9(1): 197-201.
[http://dx.doi.org/10.4103/jfmpc.jfmpc_927_19] [PMID: 32110590]
[54]
Tantigegn S, Ewunetie AA, Agazhe M, et al. Time to diabetic neuropathy and its predictors among adult type 2 diabetes mellitus patients in Amhara regional state Comprehensive Specialized Hospitals, Northwest Ethiopia, 2022: A retrospective follow up study. PLoS One 2023; 18(4): e0284568.
[http://dx.doi.org/10.1371/journal.pone.0284568] [PMID: 37115732]
[55]
Román-Pintos LM, Villegas-Rivera G, Rodríguez-Carrizalez AD, Miranda-Díaz AG, Cardona-Muñoz EG. Diabetic polyneuropathy in type 2 diabetes mellitus: Inflammation, oxidative stress, and mitochondrial function. J Diabetes Res 2016; 2016: 3425617.
[http://dx.doi.org/10.1155/2016/3425617] [PMID: 28058263]
[56]
Darivemula S, Nagoor K, Patan SK, Reddy NB, Deepthi CS, Chittooru CS. Prevalence and its associated determinants of diabetic peripheral neuropathy (DPN) in individuals having type-2 diabetes mellitus in rural south india. Indian J Community Med 2019; 44(2): 88-91.
[http://dx.doi.org/10.4103/ijcm.IJCM_207_18] [PMID: 31333282]
[57]
Kosiborod M, Gomes MB, Nicolucci A, et al. Vascular complications in patients with type 2 diabetes: Prevalence and associated factors in 38 countries (the DISCOVER study program). Cardiovasc Diabetol 2018; 17(1): 150.
[http://dx.doi.org/10.1186/s12933-018-0787-8] [PMID: 30486889]
[58]
Zhang C, Tang M, Lu X, et al. Relationship of ankle-brachial index, vibration perception threshold, and current perception threshold to glycemic variability in type 2 diabetes. Medicine 2020; 99(12): e19374.
[http://dx.doi.org/10.1097/MD.0000000000019374] [PMID: 32195933]
[59]
Nisar MU, Asad A, Waqas A, et al. Association of diabetic neuropathy with duration of type 2 diabetes and glycemic control. Cureus 2015; 7(8): e302.
[http://dx.doi.org/10.7759/cureus.302] [PMID: 26430576]
[60]
Bodman MAVM. Peripheral diabetic neuropathy. In: StatPearls. Treasure Island, FL: StatPearls Publishing 2023. Internet
[61]
Škrha J, Šoupal J, Škrha J Jr, Prázný M. Glucose variability, HbA1c and microvascular complications. Rev Endocr Metab Disord 2016; 17(1): 103-10.
[http://dx.doi.org/10.1007/s11154-016-9347-2] [PMID: 26975588]
[62]
UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317(7160): 703-13.
[http://dx.doi.org/10.1136/bmj.317.7160.703] [PMID: 9732337]
[63]
Forrest KYZ, Maser RE, Pambianco G, Becker DJ, Orchard TJ. Hypertension as a risk factor for diabetic neuropathy: A prospective study. Diabetes 1997; 46(4): 665-70.
[http://dx.doi.org/10.2337/diab.46.4.665] [PMID: 9075809]
[64]
Bello A, Biliaminu S, Wahab K, Sanya E. Distal symmetrical polyneuropathy and cardiovascular autonomic neuropathy among diabetic patients in Ilorin: Prevalence and predictors. Niger Postgrad Med J 2019; 26(2): 123-8.
[http://dx.doi.org/10.4103/npmj.npmj_30_19] [PMID: 31187753]
[65]
Shi L, Xue J, Zhao W, et al. Trends in metabolic indicators and microvascular complications in Chinese adults with newly diagnosed type 2 diabetes: A retrospective, single-centre study of twenty-years. Diab Vasc Dis Res 2023; 20(3): 14791641231179867.
[http://dx.doi.org/10.1177/14791641231179867] [PMID: 37300432]
[66]
Zhao W, Zeng H, Zhang X, et al. A high thyroid stimulating hormone level is associated with diabetic peripheral neuropathy in type 2 diabetes patients. Diabetes Res Clin Pract 2016; 115: 122-9.
[http://dx.doi.org/10.1016/j.diabres.2016.01.018] [PMID: 26822260]
[67]
Torun AN, Kulaksizoglu S, Kulaksizoglu M, Pamuk BO, Isbilen E, Tutuncu NB. Serum total antioxidant status and lipid peroxidation marker malondialdehyde levels in overt and subclinical hypothyroidism. Clin Endocrinol 2009; 70(3): 469-74.
[http://dx.doi.org/10.1111/j.1365-2265.2008.03348.x] [PMID: 18727709]
[68]
Cebeci E, Alibaz-Oner F, Usta M, Yurdakul S, Erguney M. Evaluation of oxidative stress, the activities of paraoxonase and arylesterase in patients with subclinical hypothyroidism. J Investig Med 2012; 60(1): 23-8.
[http://dx.doi.org/10.2310/JIM.0b013e31823581dd] [PMID: 21997314]
[69]
Cai J, Ma A, Wang Q, et al. Association between body mass index and diabetes mellitus in tuberculosis patients in China: A community based cross-sectional study. BMC Public Health 2017; 17(1): 228.
[http://dx.doi.org/10.1186/s12889-017-4101-6] [PMID: 28245792]
[70]
Katulanda P, Ranasinghe P, Jayawardena R, Constantine GR, Sheriff MHR, Matthews DR. The prevalence, patterns and predictors of diabetic peripheral neuropathy in a developing country. Diabetol Metab Syndr 2012; 4(1): 21.
[http://dx.doi.org/10.1186/1758-5996-4-21] [PMID: 22642973]
[71]
Polydefkis M, Hauer P, Sheth S, Sirdofsky M, Griffin JW, McArthur JC. The time course of epidermal nerve fibre regeneration: studies in normal controls and in people with diabetes, with and without neuropathy. Brain 2004; 127(Pt 7): 1606-15.
[http://dx.doi.org/10.1093/brain/awh175] [PMID: 15128618]
[72]
Mathiyalagen P, Kanagasabapathy S, Kadar Z, Rajagopal A, Vasudevan K. Prevalence and determinants of peripheral neuropathy among adult type II diabetes mellitus patients attending a non-communicable disease clinic in rural south india. Cureus 2021; 13(6): e15493.
[http://dx.doi.org/10.7759/cureus.15493] [PMID: 34268025]
[73]
Chang MC, Yang S. Diabetic peripheral neuropathy essentials: A narrative review. Ann Palliat Med 2023; 12(2): 390-8.
[http://dx.doi.org/10.21037/apm-22-693] [PMID: 36786097]
[74]
Saher G, Quintes S, Nave KA. Cholesterol: A novel regulatory role in myelin formation. Neuroscientist 2011; 17(1): 79-93.
[http://dx.doi.org/10.1177/1073858410373835] [PMID: 21343408]
[75]
Jende JME, Groener JB, Rother C, et al. Association of serum cholesterol levels with peripheral nerve damage in patients with type 2 diabetes. JAMA Netw Open 2019; 2(5): e194798.
[http://dx.doi.org/10.1001/jamanetworkopen.2019.4798] [PMID: 31150078]
[76]
Tahir MM, Khan AZ, Haider M, Shamim A, Asif M, Ali S. Frequency of peripheral neuropathy in newly diagnosed type 2 diabetes presenting in a tertiary care hospital of Lahore. Pakistan Journal of Medical and Health Sciences 2021; 15(7): 4.
[77]
McNeely MJ, Boyko EJ, Ahroni JH, et al. The independent contributions of diabetic neuropathy and vasculopathy in foot ulceration. How great are the risks? Diabetes Care 1995; 18(2): 216-9.
[http://dx.doi.org/10.2337/diacare.18.2.216] [PMID: 7729300]
[78]
Perkins BA, Olaleye D, Zinman B, Bril V. Simple screening tests for peripheral neuropathy in the diabetes clinic. Diabetes Care 2001; 24(2): 250-6.
[http://dx.doi.org/10.2337/diacare.24.2.250] [PMID: 11213874]
[79]
Javed N, Shahid A, Qaisra S. An experience with the use of biothesiometer in diabetics at a tertiary care centre. Pak J Med Health Sci 2015; 9: 423-6.
[80]
Bloom S, Till S, Sönksen P, Smith S. Use of a biothesiometer to measure individual vibration thresholds and their variation in 519 non-diabetic subjects. Br Med J 1984; 288(6433): 1793-5.
[http://dx.doi.org/10.1136/bmj.288.6433.1793] [PMID: 6428547]
[81]
Davis EA, Jones TW, Walsh P, Byrne GC. The use of biothesiometry to detect neuropathy in children and adolescents with IDDM. Diabetes Care 1997; 20(9): 1448-53.
[http://dx.doi.org/10.2337/diacare.20.9.1448] [PMID: 9283795]

Rights & Permissions Print Cite
© 2025 Bentham Science Publishers | Privacy Policy